Life treatening angioedema as side effect of angiotensin-1-receptor-blockers

Ulrich Strassen, Jens Greve & Murat Bas
Background: Angiotensin-converting-enzyme (ACE)-inhibitor-induced angioedema (AE) account for approximately 25 to 38% of all AE-patients admitted to emergency departments. Reduced metabolism of bradykinin via ACE has been suggested in the development of these. First line therapy consists of Icatibant[for full text, please go to the a.m. URL]